EOLS
Evolus, Inc.
EOLS's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over EOLS overall, supported by stronger fundamentals.
EOLS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
EOLS's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EOLS PE Valuation
EOLS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 29x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
EOLS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect EOLS to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
EOLS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q3 2026 | -$0.46 | +$0.46 |
| Q2 2026 | -$0.51 | +$0.47 |
| Q1 2026 | -$0.66 | +$0.23 |
| Q4 2025 | -$0.80 | +$0.01 |
| Q3 2025 | -$0.92 | -$0.02 |
| Q2 2025 | -$0.98 | -$0.08 |
| Q1 2025 | -$0.89 | +$0.15 |
| Q4 2024 | -$0.81 | +$0.27 |
EOLS is still losing money, but far less than before: $0.46 per share over the past year, against $4.83 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over EOLS on earnings quality, reporting a profit while its opponent remains loss making.
EOLS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78M | +13% |
| Q2 2026 | $84.1M | +21% |
| Q1 2026 | $73.1M | +6.7% |
| Q4 2025 | $90.3M | +14% |
| Q3 2025 | $69M | +13% |
| Q2 2025 | $69.4M | +3.7% |
| Q1 2025 | $68.5M | +15% |
| Q4 2024 | $78.9M | +29% |
EOLS's revenue has grown year over year every quarter since late 2020: $78M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11% | +5.9 points |
| Q2 2026 | -5.4% | +9.3 points |
| Q1 2026 | -9.4% | +13 points |
| Q4 2025 | 4.7% | +7.6 points |
| Q3 2025 | -17% | +8.7 points |
| Q2 2025 | -15% | -3.2 points |
| Q1 2025 | -22% | -7.1 points |
| Q4 2024 | -2.9% | +11 points |
EOLS's operating margin was −11% last quarter, up 5.9 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over EOLS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over EOLS on profitability, with a higher operating margin.
EOLS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | +$13.4M |
| Q2 2026 | -$3.6M | +$21.8M |
| Q1 2026 | -$10.4M | +$5.6M |
| Q4 2025 | $11.3M | +160% |
| Q3 2025 | -$15.6M | -$9.6M |
| Q2 2025 | -$25.5M | -$18.5M |
| Q1 2025 | -$16M | -$5.1M |
| Q4 2024 | $4.4M | +624% |
EOLS has burned cash in almost every quarter: −$5M over the past year, against −$53M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over EOLS on cash generation, producing positive trailing cash flow while its opponent burns cash.
EOLS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +156K shares |
| 1 year | +2.1% | +1.4M shares |
| 3 years | +16% | +9.1M shares |
| 5 years | +20% | +11.1M shares |
| Available history | +134% | +37.8M shares |
EOLS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EOLS Net Leverage
EOLS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
EOLS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 33.2 | Neutral |
EOLS's weekly RSI is 51 (neutral) and its Stochastic is 33 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EOLS PE vs Healthcare Sector
EOLS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EOLS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.29 | 1.5% below |
| 20 week MA | $7.37 | 2.6% below |
| 50 week MA | $6.31 | 14% above |
| 100 week MA | $7.99 | 10% below |
| 200 week MA | $9.59 | 25% below |
EOLS's trend is mixed: it's above one of its five weekly moving averages, and 25% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over EOLS on trend strength, trading above more of its moving averages.
EOLS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $3.55 | -70% |
| 2021 | $3.55 | $6.96 | +96% |
| 2022 | $6.96 | $6.87 | -1.3% |
| 2023 | $6.87 | $10.5 | +53% |
| 2024 | $10.5 | $11.1 | +5.3% |
| 2025 | $11.1 | $6.90 | -38% |
| 2026 YTD | $6.90 | $7.18 | +4.1% |
EOLS has finished lower in three of the last six years. It's up 4.1% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EOLS on returns for 2026, with the stronger performance.